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Background. The proper management of patients infected with dengue virus requires early detection. Here, real-time molecular
assays have proven useful but have limitations, whereas ELISAs that detect antibodies are still favored but results are obtained too
late to be of clinical value.The production of DENVNS1 peaks early during infection and its detection can combine the advantages
of both diagnostic approaches. Methods. This study compared assays currently used for detecting DENV infection at the Florida
Department of Health including anti-DENV IgM and IgG ELISAs as well as qRT-PCR, against a commercially available DENV
NS1 ELISA.These comparisons were made among a group of 21 human sera. Results. Nine of 14 (64.3%) DENV qRT-PCR+ samples
were also DENV NS1+. Interestingly, the 5 NS1− samples that were qRT-PCR+ were additionally IgM− and IgG+ suggesting a
nonprimary infection. Compared to qRT-PCR, the NS1 assay had a sensitivity of 64.3%, specificity 100%, PPV of 100%, and NPV of
58.3%. Conclusions. The NS1 ELISA performed as expected in known DENV qRT-PCR+ samples; however negative NS1 results for
qRT-PCR+ and IgG+ sera seemingly reduced the usefulness of the NS1 ELISA for nonprimary cases. We therefore conclude that
diagnosis obtained via DENV NS1 ELISA deserves further investigation.
1. Introduction
Infections caused by dengue virus continue to constitute
a worldwide threat to the public, both in human and in
economic costs. In 2017, dengue virus remains the cause
of one of the most globally significant arthropod-borne
(arbo-) viral illnesses. According to WHO, there is cur-
rently an at risk global population of 3.9 billion where an
estimated 390 million infections occur annually. Around
96 million infected persons seek clinical attention but the
majority of cases go unreported. Approximately 500,000 of
clinical patients will progress to severe illness and require
hospitalization with fatalities arising in 2.5% [1, 2]. Addi-
tionally, after a 75-year absence, local transmission of DENV
was documented in Florida, USA. During the time period
of 2009–2012, 103 autochthonous cases were documented
with the majority of those cases (27 in 2009 and 63 in
2010) associated with an outbreak of DENV serotype 1
(DENV1) in Key West (Monroe County). However, epi-
demiologically unrelated, locally acquired cases were also
documented in Broward, Hillsborough, Miami-Dade, Palm
Beach, Osceola, Martin, and Seminole counties through
2012. A second outbreak of DENV1 occurred in Martin
County during 2013 [3–5]. Two introductions of dengue are
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thought to have occurred in Martin County, the first near
Port Salerno in 2011 and the second near Jensen Beach,
the second being responsible for the outbreak. In 2016,
a case of DENV4 (Cone M, personal comm.) was locally
acquired in Key West [6] and dengue appeared again locally
in Miami-Dade during Zika virus outbreak investigations
[7].
Dengue is caused by one of four different serotypes of
small RNA viruses in the family Flaviviridae, DENV1–4. The
5󸀠 and 3󸀠 ends of the DENV genome contain untranslated
regions (UTRs) and the open reading frame first encodes
the three structural proteins, C, prM/M, and env, followed
by 7 nonstructural (NS) proteins, including the NS1 protein.
The genome is translated as a single polyprotein that is
processed and modified posttranslationally [8]. The NS1
protein itself is secreted from infected cells and is found in
serum at detectable levels that overlap with peak viremia
(and RNA detection). These NS1 levels also coincide with
the onset of detectable IgM in acute primary cases and
IgG in acute nonprimary cases [9]. It has been found that
elevated levels of serum NS1 directly indicate increased viral
burden and further establish the positive correlation between
viremia and NS1 profiles [10, 11]. NS1 is a generally conserved
protein among flaviviruses but has been found to contain
both cross-reactive and serotype-specific epitopes among
dengue viruses; these are important factors when considering
development of immunoassays [12–14]. For these reasonsNS1
is considered as having diagnostic value as a viral marker
of infection. The protein is found both intracellularly and
in a soluble form (sNS1) secreted from infected host cells
but its function remains enigmatic. The immature form of
NS1 is that of a monomer that is variably glycosylated but
readily forms heat-labile homodimers usually associated with
the surface of infected cells [8, 14]. From there, the major
oligomeric form of sNS1 is thought to be a hexamer of around
300 kDa. The hexamer consists of 3 dimeric subunits that
are noncovalently bound and are less stable than NS1 dimers
[15, 16].
Dengue is a problematic disease to manage at the clinical
level, in large part due to late manifestations of severe illness
in some patients [17]. In the past, techniques including virus
isolation and serological assays such as ELISA and plaque-
reduction neutralization assays (PRNT) typically yielded
results after clinical resolution (or development of severe
illness), leading to diagnosis with no benefit to the patient.
However, the capabilities of the laboratory have advanced to
the level of obtaining same day results in acutely infected
patients with the advent of rapid techniques that include
molecular diagnostic assays such as real-time qRT-PCR [9].
As alluded to above, the NS1 protein of DENV is also a
useful early viral marker of infection and an ELISA (Panbio
Dengue Early ELISA #E-DEN02P) that detects it is currently
available from Inverness Medical (now Alere Inc.) among
other manufacturers of similar immunoassays. These DENV
NS1 immunoassays may represent the new paradigm for
DENV diagnosis in many parts of the world, in part, by serv-
ing to combine the pros of both traditional serological assays
and those of modern molecular assays. These include early
diagnosis commensurate with the capabilities of molecular
assays coupled with decreased costs in both equipment and
reagents along with the reduction of the technical prowess
and stringency required for performing them in the clinic.
This study attempted to ascertain the potential value of the
DENV NS1 ELISA detailed Section 2.3 in diagnosing dengue
in the US state of Florida.
2. Materials and Methods
2.1. Ethics Statement. The removal of identifiers in these
previously collected serum samples resulted in the determi-
nation of this study as not meeting the definition of human
research activities and thus IRB exempt under US 45 CFR
46.101(4). This ruling was determined by the University of
South Florida IRB.
2.2. Sample Selection. A series of 21 serum samples previously
assayed at the Florida Department of Health- (FLDOH-)
Bureau of Public Health Laboratories- (BOPHL-) Tampa
for DENV by qRT-PCR and either anti-DENV IgM and
IgG ELISA in concert (20/21) or IgM only (1/21) were
subsequently subjected to DENV NS1 detection by ELISA.
Corresponding DENV serotypes of positive samples were
also obtained via qRT-PCR. Eight of 14 qRT-PCR+ samples
were positive for DENV1, five were DENV4+, and one was
DENV2+. No samples that were identified as DENV3+ were
included in this study. Dengue qRT-PCR− samples belonged
to either of the following diagnostic categories: anti-DENV
IgG+ (𝑛 = 2) or samples negative for all routine DENV
diagnostic assays. The latter samples were obtained from
either the clinical archive (𝑛 = 2) or a serosurvey (𝑛 = 3)
conducted in Martin County, Florida, during the course of
an outbreak of DENV1. The DENV IgG and IgM ELISAs
were adapted from protocols provided by CDC-Arboviral
Diseases Branch (Ft. Collins, CO) and TaqMan-based DENV
serotype-specific qRT-PCR was performed using an FDA-
approved protocol provided by CDC-Dengue Branch (San
Juan, Puerto Rico).
2.3. DENV NS1 ELISA. The Panbio dengue early ELISA
(Inverness Medical, Sinnamon Park, QLD, Australia, #E-
DEN02P) was used to determine the presence of DENV
NS1 in individual serum samples. Each sample was run in
duplicate, according to manufacturer’s instructions with the
following changes specific to our study. (Samples, positive
controls, and negative controls were added to wells in dupli-
cate and calibrators were added in quadruplicate, all at 100𝜇L.
TheELISA sample plates were read at 450 nmwith a reference
filter of 620 nm. Each sample OD value (absorbance) was
averaged between duplicate wells and then divided by the
cut-off value to obtain index values.) Index values < 0.9 were
ruled as negative, between 0.9 and 1.1 as equivocal, and values
above 1.1 as positive for DENV NS1 detection. The results
of this assay were then compared to those of DENV virus
RNA detection via qRT-PCR as well as anti-DENV IgM and
IgG ELISAs previously performed at the FLDOH-BOPHL-
Tampa.
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Table 1: DENV NS1 detection in selected serum samples as determined by ELISA and in comparison to clinical molecular (qRT-PCR) and
serological (anti-DENV IgM and IgG) results. The table below details the results of DENVNS1 detection by ELISA against qRT-PCR, IgM, and
IgGDENV assays for a group of serum samples selected for inclusion and based on the following criteria: (1) denotes samples that were positive
by qRT-PCR for DENV as determined by BOPHL-Tampa; (2) denotes samples that were positive for DENV by IgG detection only as determined
by BOPHL-Tampa; (3) denotes samples that were DENV negative received by BOPHL-Tampa for all DENV-specific assays; (4) denotes samples
that were collected fromMartin County serosurvey and were found to be DENV negative by all DENV-specific assays. Index values represent the
mean of duplicate values obtained when reading samples at 450 nm and taking calibrators into account. Negative samples had an index value
> 0.9, those between 0.9 and 1.1 were equivocal, and those above 1.1 were positive for NS1 detection. Results are listed as either positive (+) or
negative (neg) for each ELISA. Positive qRT-PCR results are reported either as neg or positive by listing serotype and𝐶
𝑇
value results. Samples
that were qRT-PCR+ but NS1 neg are highlighted in bold font within the table. Note that no single assay here was capable of diagnosingDENV
infection alone.
Sample Index value NS1 ELISA qRT-PCR (𝐶
𝑇
) IgM ELISA IgG ELISA
(1-1) 5.98 + DENV4 (20.40) + +
(1-2) 5.91 + DENV1 (14.19) Neg Neg
(1-3) 0.08 Neg DENV1 (33.17) Neg +
(1-5) 0.09 Neg DENV1 (34.96) Neg +
(1-6) 5.93 + DENV1 (26.06) + Neg
(1-7) 5.93 + DENV1 (30.40) + Neg
(1-8) 4.51 + DENV1 (22.32) + Neg
(1-9) 5.38 + DENV1 (31.90) + Neg
(1-10) 0.17 Neg DENV1 (25.53) Neg +
(1-11) 5.97 + DENV4 (29.79) + +
(1-12) 5.92 + DENV4 (20.74) Neg +
(1-13) 0.21 Neg DENV4 (19.69) Neg +
(1-14) 0.25 Neg DENV2 (25.13) Neg +
(1-15) 6.00 + DENV4 (21.03) + +
(2-3) 0.43 Neg Neg Neg +
(2-4) 0.13 Neg Neg Neg +
(3-1) 0.05 Neg Neg Neg Neg
(3-2) 0.09 Neg Neg Neg Neg
(4-1) 0.05 Neg Neg Neg Neg
(4-2) 0.06 Neg Neg Neg Neg
(4-3) 0.06 Neg Neg Neg N/A
3. Results
In our study, the DENV NS1 ELISA (Tables 1 and 2)
(see Graphical Abstract in Supplementary Material available
online at https://doi.org/10.1155/2017/8072491) found 9 of 14
sera to be positive for DENV that were also qRT-PCR+ and
0 of 2 that were previously positive by IgG only (9/16 total
DENV+ samples). Five samples that were DENV− negative
in all 3 comparison assays, including 2 clinical samples and
3 from the Martin County serosurvey, were also negative via
DENV NS1 ELISA. Each of the DENV qRT-PCR+ samples
that were found to be NS1 ELISA− was also negative for IgM
(5/14). Interestingly, however, these 5 qRT-PCR+ samples
were positive for IgG (and IgM−) by ELISA, suggesting
nonprimary infection. Additionally, each of the 3 dengue
serotypes represented in this study was found within this
subgroup (3 of 5 samples were DENV1, 1 = DENV2, and
1 = DENV4). On the other hand, one sample that was
NS1+ presented with the same profile (i.e., qRT-PCR+, IgM−,
and IgG+). All seven qRT-PCR− samples were also negative
for DENV NS1. Please take note that the desired direct
comparison between assays was made between those capable
of early detection (NS1 ELISA versus qRT-PCR). Therefore,
while both assays failed to detect dengue in 2 samples that
were IgG+ only, the “true negative” sample number of (𝑛 = 7)
was left to stand for calculations so as not to skew the NPV
artificially in favor of qRT-PCR. In all and when compared
to the results of qRT-PCR, the NS1 assay was found to have a
sensitivity of 64.3%, specificity of 100%, a positive predictive
value (PPV) of 100%, and a negative predictive value (NPV) of
58.3% in this small and varied sample set (Graphical Abstract
and Table 3).
4. Discussion
Like the results found here, previous reports of the investiga-
tional use of commercially available DENV NS1 immunoas-
says such as those in Brazil [18] and Malaysia [19] showed
favorable results when compared against standard diagnostic
methods. The former group used the Platelia Dengue NS1
Ag microplate EIA (Bio-Rad, Hercules, CA) and the latter
the SD Bioline Dengue Duo (Standard Diagnostics, Yongin-
si, Republic of Korea). These groups obtained results with
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Table 2: Breakdown of DENV serological diagnostic status (any com-
bination of DENV NS1, anti-DENV IgM, and/or –IgG) versus detec-
tion of DENV RNA via qRT-PCR. The table below details first the
comparison of DENV NS1 detection via ELISA compared to results
obtained for the respective sample set via qRT-PCR (𝑛 = 21), set as a
gold-standard.The table details a further breakdown of these results
by including anti-DENV IgM and IgG status of the samples. Nine (9
out of 14) qRT-PCR+ samples were also DENV NS1+ (64.3%) and
all 7 samples that were negative by qRT-PCR were also found to be
negative for DENV NS1. Notably, all 5 DENV NS1− samples that
were qRT-PCR+ were also anti-DENV IgM− and IgG+, while only 1
positive NS1 sample was found to have that same profile, indicating
that nonprimary infections may affect the sensitivity of the DENV
NS1 ELISA. ∗𝑃𝑙𝑒𝑎𝑠𝑒 note that 1 of the DENV qRT-PCR− samples was
not assayed for DENV anti-IgG.
DENV ELISA results





DENV NS1+ 9/14 (64.3%) 0/7 (0%)
DENV NS1− 5/14 (35.7%) 7/7 (100%)
DENV NS1+, IgM+ 7/14 (50%) 0/7 (0%)
DENV NS1+, IgM− 2/14 (14.3%) 0/7 (0%)
DENV NS1−, IgM+ 0/14 (0%) 0/7 (0%)
DENV NS1−, IgM− 5/14 (35.7%) 7/7 (100%)
DENV NS1+, IgG+ 4/14 (28.6%) 0/6∗ (0%)
DENV NS1+, IgG− 5/14 (35.7%) 0/6∗ (0%)
DENV NS1−, IgG+ 5/14 (35.7%) 2/6∗ (33.3%)
DENV NS1−, IgG− 0/14 (0%) 4/6∗ (66.7%)
DENV NS1+, IgM+,
IgG+ 3/14 (21.4%) 0/6
∗ (0%)
DENV NS1+, IgM−,
IgG+ 1/14 (7%) 0/6
∗ (0%)
DENV NS1−, IgM+,
IgG+ 0/14 (0%) 0/6
∗ (0%)
DENV NS1−, IgM−,
IgG+ 5/14 (35.7%) 2/6
∗ (33.3%)
DENV NS1+, IgM+,
IgG− 5/14 (35.7%) 0/6
∗ (0%)
DENV NS1+, IgM−,
IgG− 0/14 (0%) 0/6
∗ (0%)
DENV NS1−, IgM+,
IgG− 0/14 (0%) 0/6
∗ (0%)
DENV NS1−, IgM−,
IgG− 0/14 (0%) 4/6
∗ (66.7%)
sensitivities of 95.9% and 65.41% and specificities of 81.1%
and 98.75%, respectively (whereby for the SD Bioline assay,
a multiplex assay, only NS1 was considered). In 2010, the
Platelia assay was approved for the screening of 80,000
Puerto Rican blood donors. At the time of FDA approval for
the particular study, the test was already in use in approx-
imately 40 countries around the world [20]. The USNIH
notes on https://www.clinicaltrials.gov that the study has
been completed but official results are yet to be reported [21].
In Lima et al. [22], two of the previouslymentioned assays, the
PanBio ELISA and the Platelia EIA, were compared against
another immunoassay, the Dengue NS1 STRIP (Bio-Rad,
Hercules, CA). The STRIP is an immunochromatographic
test similar to the previously mentioned SD Bioline Dengue
Duo. While all obtained specificities are near 100%, here
they found the STRIP assay to have the highest sensitivity
(89.6%), followed by the Platelia EIA at 83.6% and the
Panbio ELISA at 72.3%. This group also reported that the
assays were less sensitive in detecting DENV3 cases and that
the Platelia assay detected primary cases at a statistically
significant higher percentage than nonprimary cases.
It should also be noted that concerns about the sensitivity
of the Platelia EIA arose in a study in Aracaju, Brazil,
where 58 of 119 NS1 negative samples were instead found later
to be DENV4+ by confirmatory tests, and their reasoning
pointed to an issue with the detection of nonprimary cases
[23]. As mentioned above, this was also seemingly evident
in our study where all 5 NS1 ELISA− samples known to be
qRT-PCR+ were also IgG+ in ELISA. However, a subsequent
report published after obtaining the results reported here
indicated that this drawback can be alleviated by preheating
samples at 100∘C for 5m [24]. This would indicate that the
assay may require dissociation of antigen-antibody com-
plexes and/or preferentially detects monomeric NS1 over its
dimeric form.The former seems very likely as, in nonprimary
infections, NS1 bound by IgG antibodies produced during the
early phases would reduce the pool of free and detectable
serum levels of this protein. On the other hand, their
data suggested that, with heating, the assay is preferentially
detecting NS1 monomers in both types of dengue infection
[14]. It would be important to empirically determine that
the heating step reported above is producing dissociation
of antigen-antibody complexes and/or dissociation of free
dimeric NS1 into constituent monomers and that this step is
essential for increasing sensitivity in both types of infection.
There also remains the concern that no single assay
included in this study was alone sufficient for diagnosis. This
was evident where 2 out of 7 qRT-PCR− samples were found
to be DENV+ only via IgG detection. This in turn affected
the comparison between the test under question (DENVNS1
ELISA) and the gold-standard used here for early detection
(qRT-PCR). Wang and Sekaran [19] abrogated this assay-
related issue to a large extent through the use of a “one-stop”
rapid test able to detect not only NS1 but also IgM and/or
IgG. This in turn increased the sensitivity of their combined
assay and identified, concurrently, more positive individuals.
This and othermultifaceted approaches to DENVdiagnostics
seem to be the proper direction moving forward and we
encourage further investigation.
Regarding our study, we accept that larger scale studies
typically include greater numbers of negative samples when
characterizing new assays. Here, though, both the limited
number of reagents and DENV+ samples available for study
compelled us to approach the study from the opposite direc-
tion. Additionally, as part of a larger study, these samples were
also subject to analyses, such as immunological profiling [25]
and experimental DENV NS1 detection (Jason H. Ambrose et
al., unpublished data) further supporting the approach used
here. Despite the small sample size included, we nevertheless
conclude that assays detecting DENV NS1 should eventually
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Table 3: Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values for PanbioDENVNS1 ELISAwhen compared to detection
of DENV RNA via qRT-PCR. Note that the “true negative” value of 𝑛 = 7 was left to stand in order to prevent skewing calculations in favor of
qRT-PCR even though both assays failed to diagnose dengue correctly in 2 IgG+ samples.
DENV qRT-PCR+ (𝑛 = 14) DENV qRT-PCR− (𝑛 = 7)
DENV NS1 ELISA+ 9 0 PPV = 100%
DENV NS1 ELISA− 5 7 NPV = 58.3%
Sensitivity = 64.3% Specificity = 100%
be incorporated within the algorithms of laboratories per-
forming dengue diagnostics, including BOPHL-Tampa. We
also propose that they are investigated for further utility,
especially in conjunction with not only other potential
diagnostic markers, but also those of prognostic value, in
order to better inform the clinic on identifying and properly
managing patients infected with dengue.
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